ID   HMC-1
AC   CVCL_0003
SY   HMC1
DR   BTO; BTO:0001669
DR   MCCL; MCC:0000199
DR   BioSample; SAMN03473342
DR   cancercelllines; CVCL_0003
DR   ChEMBL-Cells; CHEMBL4295401
DR   ChEMBL-Targets; CHEMBL4296432
DR   Cosmic; 821806
DR   Cosmic; 821913
DR   Cosmic; 822147
DR   Cosmic; 1122161
DR   DSMZ; ACC-283
DR   DSMZCellDive; ACC-283
DR   Lonza; 502
DR   PubChem_Cell_line; CVCL_0003
DR   TOKU-E; 3534
DR   Wikidata; Q54889906
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3131594;
RX   PubMed=7691885;
RX   PubMed=8191224;
RX   PubMed=8950460;
RX   PubMed=25149487;
WW   https://www.proteinatlas.org/learn/cellines
CC   Doubling time: 3-4 days (PubMed=3131594).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous (PubMed=7691885).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=7691885).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: DSMZ; ACC-283; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Mast cell; CL=CL_0000097.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 10,11
ST   D16S539: 10,12
ST   D18S51: 14,20
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 17,25
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 12
ST   FGA: 18,20
ST   Penta D: 11
ST   Penta E: 9,19
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C3169; Mast cell leukemia
DI   ORDO; Orphanet_98851; Mast cell leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3131594; DOI=10.1016/0145-2126(88)90050-1;
RA   Butterfield J.H., Weiler D., Dewald G., Gleich G.J.;
RT   "Establishment of an immature mast cell line from a patient with mast
RT   cell leukemia.";
RL   Leuk. Res. 12:345-355(1988).
//
RX   PubMed=7691885; DOI=10.1172/JCI116761;
RA   Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H.,
RA   Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K.,
RA   Kanayama Y., Matsuzawa Y., Kitamura Y., Kanakura Y.;
RT   "Identification of mutations in the coding sequence of the
RT   proto-oncogene c-kit in a human mast cell leukemia cell line causing
RT   ligand-independent activation of c-kit product.";
RL   J. Clin. Invest. 92:1736-1744(1993).
//
RX   PubMed=8191224; DOI=10.1111/j.1365-3083.1994.tb03404.x;
RA   Nilsson G., Blom T., Kusche-Gullberg M., Kjellen L., Butterfield J.H.,
RA   Sundstrom C., Nilsson K., Hellman L.;
RT   "Phenotypic characterization of the human mast-cell line HMC-1.";
RL   Scand. J. Immunol. 39:489-498(1994).
//
RX   PubMed=8950460; DOI=10.1007/BF02505297;
RA   Weber S., Babina M., Kruger-Krasagakes S., Grutzkau A., Henz B.M.;
RT   "A subclone (5C6) of the human mast cell line HMC-1 represents a more
RT   differentiated phenotype than the original cell line.";
RL   Arch. Dermatol. Res. 288:778-782(1996).
//
RX   PubMed=25149487; DOI=10.1007/978-1-4939-1173-8_8;
RA   Passante E.;
RT   "Mast cell and basophil cell lines: a compendium.";
RL   Methods Mol. Biol. 1192:101-113(2014).
//